Pauline Wils
YOU?
Author Swipe
View article: IMPACT OF ENDOMETRIOSIS ON THE PROGRESSION OF INFLAMMATORY BOWEL DISEASES: A MULTICENTER RETROSPECTIVE STUDY
IMPACT OF ENDOMETRIOSIS ON THE PROGRESSION OF INFLAMMATORY BOWEL DISEASES: A MULTICENTER RETROSPECTIVE STUDY Open
Introduction: Women with endometriosis have a higher risk of developing inflammatory bowel diseases (IBD). This study aimed to better understanding the impact of endometriosis on the course of IBD. Methods: We conducted a retrospective coh…
View article: Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID
Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID Open
INTRODUCTION: Intravenous infliximab (IFX) is the cornerstone for treating patients with perianal Crohn's disease (pCD). Data on the recently launched subcutaneous (SC) IFX for pCD are limited. The aim of our study was to evaluate the effe…
View article: Effectiveness and Safety of a Second <scp>JAK</scp> Inhibitor in Ulcerative Colitis: The <scp>J2J</scp> Multicentre Study
Effectiveness and Safety of a Second <span>JAK</span> Inhibitor in Ulcerative Colitis: The <span>J2J</span> Multicentre Study Open
Background While three Janus kinase inhibitors (JAKi) have demonstrated efficacy in ulcerative colitis (UC), scarce data exist regarding JAKi intraclass switching. Aim To evaluate the effectiveness and safety of a second JAK inhibitor in U…
View article: Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study
Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study Open
Background: Prospective data about the acceptance and outcomes of switching from the adalimumab (ADA) reference product (RP) to multiple ADA biosimilars in inflammatory bowel disease (IBD) patients are lacking. Objectives: To evaluate the …
View article: High‐Resolution Manometry With Solid Provocative Test in Patients With Mid‐Thoracic and Epiphrenic Esophageal Diverticula
High‐Resolution Manometry With Solid Provocative Test in Patients With Mid‐Thoracic and Epiphrenic Esophageal Diverticula Open
Background The number of studies exploring esophageal motility disorders using high‐resolution manometry (HRM) in patients with esophageal diverticula (ED) is limited. The goal of this study was to describe motility disorders using HRM in …
View article: P0706 Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study
P0706 Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study Open
Background Subcutaneous (SC) vedolizumab (VDZ) has demonstrated its efficacy and safety in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). This study aimed to evaluate the effectiveness and safety of SC V…
View article: P0654 Switching from intravenous to subcutaneous infliximab: physicians’ practice and patients’ satisfaction - Results from a nationwide transectional study
P0654 Switching from intravenous to subcutaneous infliximab: physicians’ practice and patients’ satisfaction - Results from a nationwide transectional study Open
Background Subcutaneous (SC) infliximab is efficient and safe in inflammatory bowel diseases (IBD), but no guidelines exist regarding practical modalities of switching from IV to SC infliximab. This study aimed to describe current practice…
View article: Changes Over Time in the Lémann Index and the Inflammatory Bowel Disease Disability Index in a Prospective Cohort of Patients With Crohn’s Disease
Changes Over Time in the Lémann Index and the Inflammatory Bowel Disease Disability Index in a Prospective Cohort of Patients With Crohn’s Disease Open
Background Crohn’s disease (CD) is a progressive, destructive, and disabling disorder. Our study aimed to assess changes over time in the Lémann index (LI) and the Inflammatory Bowel Disease Disability Index (IBD-DI) in a cohort of CD pati…
View article: P1122 Comorbidities Associated with Pediatric Onset Inflammatory Bowel Diseases: A Population-Based Study
P1122 Comorbidities Associated with Pediatric Onset Inflammatory Bowel Diseases: A Population-Based Study Open
Background Inflammatory bowel disease (IBD) can be associated with various disorders, including dermatological, rheumatological, or psychiatric conditions. However, little is known about the incidence of these co-morbidities in paediatric-…
View article: P836 Prospective evaluation of the switch from adalimumab originator to different biosimilars in IBD patients : acceptability and persistance at 1 year
P836 Prospective evaluation of the switch from adalimumab originator to different biosimilars in IBD patients : acceptability and persistance at 1 year Open
Background The use of biological therapies represents a major source of direct healthcare costs for inflammatory bowel disease (IBD) in industrialised countries. Several adalimumab (ADA) biosimilars are available for Crohn's disease (CD) a…
View article: P1125 Incidence and Neoplastic Risk Associated with Colonic Stricture in Pediatric-Onset Crohn's Disease: A Population-based Study
P1125 Incidence and Neoplastic Risk Associated with Colonic Stricture in Pediatric-Onset Crohn's Disease: A Population-based Study Open
Background The identification of colonic stricture in patients with Crohn's disease (CD) often leads to surgery due to concerns about associated neoplasia. Nevertheless, information regarding the neoplastic risk associated to colonic stric…
View article: P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID Open
Background Several adalimumab preparations are now available on the market for patients with inflammatory bowel disease. Comparative satisfaction and tolerability are unknown. The aim of this study was to investigate inflammatory bowel dis…
View article: DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial
DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial Open
Background In patients admitted for acute severe ulcerative colitis (ASUC) responding to intravenous (IV) steroids, the most effective treatment is unknown. In thiopurine-naive patients, thiopurines are appropriate to maintain remission ac…
View article: P900 A PROOF-OF-CONCEPT, PLACEBO-RANDOMIZED CONTROLLED TRIAL TARGETING ADHERENT AND INVASIVE ESCHERICHIA COLI (AIEC) WITH ANTIBIOTICS IN CROHN’S DISEASE: the TEOREM TRIAL
P900 A PROOF-OF-CONCEPT, PLACEBO-RANDOMIZED CONTROLLED TRIAL TARGETING ADHERENT AND INVASIVE ESCHERICHIA COLI (AIEC) WITH ANTIBIOTICS IN CROHN’S DISEASE: the TEOREM TRIAL Open
Background Adherent-invasive E. coli (AIEC) are found in the ileal mucosa of 21-63% of patients with ileal Crohn’s disease (CD) vs 0-16% of controls. This trial tested the efficacy of antibiotics targeting AIEC in CD patients with ileal in…
View article: P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial
P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial Open
Background Achieving deep and continuous remission with tight control could allow de-escalation in patients with UC. The in-TARGET study was a prospective two-phase trial in UC patients initiating golimumab (GLM), that aimed to determine t…
View article: Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID Open
Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown. Objectives: This study investigated IBD patient satisfaction with appr…
View article: P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study Open
Background Vedolizumab is often used as the first-line advanced therapy for patients with moderate to severe ulcerative colitis (UC). There is currently no data reporting the efficacy and safety of second-line treatments after initial vedo…
View article: P733 Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study
P733 Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study Open
Background We recently demonstrated that switching from intravenous to subcutaneous infliximab is safe and well-accepted at short-term in IBD patients including those with intensified IV regimen. However, the long-term risk of relapse in t…
View article: P1151 Incidence and risk factors of thromboembolic events in Pediatric-Onset Inflammatory Bowel Disease: a population-based study
P1151 Incidence and risk factors of thromboembolic events in Pediatric-Onset Inflammatory Bowel Disease: a population-based study Open
Background Patients with inflammatory bowel disease (IBD) are known to be more susceptible to thromboembolic events. However, limited data on the incidence and risk factors for both venous (VTE) and arterial thromboembolic events (ATE) hav…
View article: Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID
Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID Open
Background Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials in ulcerative colitis.…
View article: Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease Open
Background and Aims The accumulation of multiple randomized controlled trials in the field of inflammatory bowel diseases provides an opportunity to compare treatment effects between phase 2 and 3 trials. We aimed to determine whether trea…
View article: A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis Open
INTRODUCTION: Phase 2 trials are fundamental to the rational and efficient design of phase 3 trials. We aimed to determine the relationship of treatment effect size estimates from phase 2 and phase 3 clinical trials on advanced therapeutic…
View article: Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID Open
Background Fatigue is commonly reported by patients with inflammatory bowel disease [IBD], but the determinants of IBD-related fatigue have yet to be determined. Aims To identify the factors associated with fatigue in a large population of…
View article: P015 CITE-seq analysis revealed immune cell diversity in colonic mesenteric lymph nodes from IBD patients
P015 CITE-seq analysis revealed immune cell diversity in colonic mesenteric lymph nodes from IBD patients Open
Background Mononuclear phagocytes (MNPs), including dendritic cells (DCs), monocytes (Mo), and macrophages (Mac), are key inducers of the adaptive immune response. MNPs could circulate between blood, mucosa, and mesenteric lymph nodes (MLN…
View article: P207 Colonic location at diagnosis of pediatric-onset Crohn’s disease is associated with a pejorative disease course: a two decades population-based study
P207 Colonic location at diagnosis of pediatric-onset Crohn’s disease is associated with a pejorative disease course: a two decades population-based study Open
Background Crohn's disease (CD) location would influence the risk of complications and therapeutic strategies. The objective of this study was to compare the clinical presentation at diagnosis and the natural history of colonic CD in compa…